b'with B-cell lymphomas, Chabon said, givingThe advantages supported the companysleader in CRISPR technology, a scientific dis-patients and physicians a crucial advantage. rapid growth. Foresight was able to movecovery that facilitates gene editing.This technology will allow the physician tointo an existing lab space, quickly scaling itsCEO Sri Kosaraju said the $150 million deal operations, and tapped into a vast talent poolThe biotechnology industry is transforming start treatment much earlier, and the earlierthat came with less competition than in theprovided crucial capital to propel Inscriptaspeoples lives in Colorado and beyond.you can start treatment, the better we believetechnology forward but also added a new the outcomes will be for the patient, he said. Bay Area. Those two factors have stretchedstable of investors that have already created Foresights Series A much further than if itimmense value for the company. BIOs member companies develop With a strong founding team alongside himwas raised in California and left the companybreakthroughs every day.that had led previous startup exits, Chabonin an advantageous position as it prepares toIts not just money, its really the profile of said Foresight had little trouble attractingraise its next round of financing. those investors and what they can help youBiotechnology innovators are bringing initial investors and was able to go straightThats allowed us to go a lot further with thewith as you grow. With the markets the waytreatments and vaccines to cure patients to a Series A raise. As a first-time founderthey are, you value that even more, he said. and CEO himself, Chabon said he quicklymoney weve raised than if we were in theThis is where the value comes, in the tougharound the globe, creating sustainable fuels learned the efficiency needed to manageBay, Chabon said. We wouldve already hadtimes. You need to lean on your investors and ato protect our climate, and developing an involved investment process, building anto go raise another round in the Bay Area, Ilot of your partners. You look for support, help,agricultural innovations to nourish humanity.FAQ file hed frequently share with investors.can say that pretty confidently. guidance, and advice, thats just the reality.When the company made the decision toInscripta: SettingWith a background on Wall Street prior toBIO. Where breakthroughs begin.relocate to Colorado, he was met with a flurrythe Standard joining Inscripta in 2020, Kosaraju said bio-of questions. science investment has made great strides in Some investors received that decision betterInscriptas $150 million Series E raise inrecent history. What was once an area where than others, there were certainly pushback2021 was a landmark moment not only foronly a few brave investors dabbled has now from some investors that didnt like the ideathe Boulder-based company, but also for thebecome a hotbed for deal flow and crucial, of operationalizing a company in Colorado,states life sciences community. It markedlifesaving innovation. Kosaraju added that he said. There were others that embracedone of the largest private capital deals in thebiotech was once the hardest thing to raise it and saw the advantages. industrys history in Colorado and cementedmoney for in his experience.Inscripta as a major success story. After its founding in 2015, Inscripta has raised nearlyThat has changed, both in Colorado and $500 million in outside capital. That Series Enationwide.deal, led by Fidelity Management & ResearchInvestments in these markets all react to Company LLC. and funds and accountsthe same thing, success. When you haveWe are committed to:advised by T. Rowe Price Associates, wassuccess, more money comes in. You have to announced in tandem with the first com-mercial shipment of Inscriptas Onyx platform,demonstrate that, and you have to be able toBetter outcomes for our worldshow returns, progress and an opportunity the worlds first benchtop system for scalablethat is significant, he said. I do believe life digital genome engineering. The companysciences is the next tech [for investors], the had been working on Onyx for nearly fouropportunity is vast.Life-transforming technologiesyears, mostly in stealth, as it aims to be a Its not just money, its reallyInsight-driven carethe profile of those investorsColorado Deals thatExperiences that put people firstand what they can help youMade Headlines with as you grow. With theIncluded a Record-markets the way they are,Breaking SPACSomaLogicyou value that even more.RAISED:$630 Million 2022 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. UC202302922CLOSED:September 2021SRI KOSARAJU, CEO, INSCRIPTAUC202202372 EN2021 Medtronic. MinneUC202302922 - CBSA Half Page Ad_v2.indd 1apolis,Caution: F MN.All Rights Rederal Law (USA) reserved.estricts these devices for sale by or on the or Printed in USA.der of a physician. Refer to product instruction7/6/22 3:23 PMmanual/packageinsert for instructions, warnings, precautions and contraindications.2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic.34 BIOSCIENCECOLORADO 2022-2023 UC201809621a EN03.2019 2022-2023 BIOSCIENCECOLORADO 35'